Clinical Trial Update: Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Adebrelimab combined with non-platinum chemotherapy and Fuzuloparib for recurrent platinum-resistant ovarian cancer; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-resistant Ovarian Cancer

Drugs mentioned

• Adebrelimab (adebrelimab)
• Fuzuloparib

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Platinum-resistant Ovarian Cancer (PROC), Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING